Compare · AVIR vs NVO
AVIR vs NVO
Side-by-side comparison of Atea Pharmaceuticals Inc. (AVIR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVIR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 571.7x AVIR ($389.7M).
- Over the past year, AVIR is up 42.7% and NVO is down 22.5% - AVIR leads by 65.2 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 1 for AVIR).
- NVO has more recent analyst coverage (25 ratings vs 13 for AVIR).
- Company
- Atea Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $4.88+3.39%
- $50.31-2.25%
- Market cap
- $389.7M
- $222.81B
- 1M return
- +15.09%
- +15.47%
- 1Y return
- +42.69%
- -22.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 1
- 4
- Recent ratings
- 13
- 25
Atea Pharmaceuticals Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AVIR
- Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
- Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
- Director Lucidi Bruno converted options into 29,600 shares, increasing direct ownership by 26% to 142,350 units (SEC Form 4)
- SEC Form 4 filed by Director Berman Howard
- Director Berger Franklin M converted options into 29,600 shares, increasing direct ownership by 6% to 536,097 units (SEC Form 4)
- Director Adams Jerome M. converted options into 29,600 shares, increasing direct ownership by 47% to 92,350 units (SEC Form 4)
- SEC Form 4 filed by Director Kirsch Arthur S
- Director Murphy Polly A. converted options into 29,600 shares, increasing direct ownership by 32% to 121,745 units (SEC Form 4)
- Director Polsky Bruce converted options into 29,600 shares, increasing direct ownership by 31% to 124,806 units (SEC Form 4)
- Director Duncan Barbara Gayle converted options into 29,600 shares, increasing direct ownership by 47% to 92,350 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S